Eli Lilly & Co. (LLY) Sinks 11% on Solanezumab Failure

November 23, 2016 6:54 AM EST

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Eli Lilly & Co. (NYSE: LLY) falls 11% after the company announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Trader Talk

Add Your Comment